Evidence map›Paper›PMID 27896639›Full record

GuidelineClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2016

SEOM Clinical Guideline for bone metastases from solid tumours (2016).

C Grávalos, C Rodríguez, A Sabino, M Á Seguí, J A Virizuela, A Carmona, J Cassinello, D Isla, C Jara, M Martín

Open access · hybridAbstract readPractice Guideline
In one paragraph

Guideline in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 3 pooled it
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 51 citations in OpenAlex.

  1. Surgical management of tibial metastases: a systematic review.Acta bio-medica : Atenei Parmensis · 2022
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Management of bone health in cancer survivorship: a systematic review of clinical guidelines.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. BeTTer Outcomes Workgroup Health Quality Initiative to optimize bone health for prostate cancer patients in the British Columbia Cancer System.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2023
    Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. The spine instability neoplastic score (SINS) in the assessment of response to radiotherapy for bone metastases.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2017
    Article
  19. Article
  20. [Progress of quantitative measurement of bone usingSheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 9 institutions in 1 country.

C GrávalosMedical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain. cristina.gravalos@salud.madrid.org.
C RodríguezHospital Universitario de Salamanca, Salamanca, Spain.
A SabinoGrupo ONCOAVANZE, Seville, Spain.
M Á SeguíCorporació Sanitària Parc Taulì, Sabadell, Spain.
J A VirizuelaComplejo Hospitalario Regional Virgen Macarena, Seville, Spain.
A CarmonaHospital Universitario J.M. Morales Meseguer, Murcia, Spain.
J CassinelloHospital Universitario de Guadalajara, Guadalajara, Spain.
D IslaHospital Clínico Universitario Lozano Blesa, Saragossa, Spain.
C JaraHospital Universitario Fundación Alcorcón, Madrid, Spain.
M MartínHospital Universitario Gregorio Marañón, Madrid, Spain.
Complejo Hospitalario de Salamanca · ESCorporació Sanitària Parc Taulí · ESHospital Clínico Universitario Lozano Blesa · ESHospital General Universitario Gregorio Marañón · ESHospital General Universitario Morales Meseguer · ESHospital Universitario 12 De Octubre · ESHospital Universitario de Guadalajara · ESHospital Universitario Fundación Alcorcón · ESHospital Universitario Virgen Macarena · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bone metastases are common in many advanced solid tumours, being breast, prostate, thyroid, lung, and renal cancer the most prevalent. Bone metastases can produce skeletal-related events (SREs), defined as pathological fracture, spinal cord compression, need of bone irradiation or need of bone surgery, and hypercalcaemia. Patients with bone metastases experience pain, functional impairment and have a negative impact on their quality of life. Several imaging techniques are available for diagnosis of this disease. Bone-targeted therapies include zoledronic acid, a potent biphosfonate, and denosumab, an anti-RANKL monoclonal antibody. Both reduce the risk and/or delay the development of SREs in several types of tumours. Radium 233, an alpha-particle emitter, increases overall survival in patients with bone metastases from resistant castration prostate cancer. Multidisciplinary approach is essential and bone surgery and radiotherapy should be integrated in the treatment of bone metastases when necessary. This SEOM Guideline reviews bone metastases pathogenesis, clinical presentations, lab tests, imaging techniques for diagnosis and response assessment, bone-targeted agents, and local therapies, as radiation and surgery, and establishes recommendations for the management of patients with metastases to bone.

Indexed as

Bone NeoplasmsHumansNeoplasmsSpainBiphosphonatesBone metastasesDenosumabRadium 223Skeletal-related events (SREs)Zoledronic acid

Identifiers

PMID27896639
PMCPMC5138247
OpenAlexW2558977844

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.